Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Terlipressin Acetate

FDA-approved product (powder, intravenous), marketed as Terlivaz.

Registered studies
7
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Terlipressin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hepatorenal syndrome
  • Kidney failure
  • Renal insufficiency

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Vasopressin and analogues
FDA pharmacologic class
Vasopressin Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae49.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

7registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Terlipressin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Terlipressin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome

    NCT07460908 · start 2025-05-01

    Registered record
    Registry ID
    NCT07460908
    Conditions
    Hepatorenal Syndrome
    Interventions
    terlipressin; Octreotide (drug)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-05-01
    Completion
    2025-10-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatorenal Syndrome
    Interventionterlipressin; Octreotide (drug)
    PhaseNot applicable
    Registry statusCompleted

  • Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

    NCT05875948 · start 2023-06-30

    Registered record
    Registry ID
    NCT05875948
    Conditions
    Hepatorenal Syndrome; Acute Kidney Injury
    Interventions
    R2R01; Terlipressin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-06-30
    Completion
    2024-12
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatorenal Syndrome; Acute Kidney Injury
    InterventionR2R01; Terlipressin
    PhasePhase 2
    Registry statusUnknown

  • Terlipressin for Refractory Septic Shock

    NCT04339868 · start 2020-04-03

    Registered record
    Registry ID
    NCT04339868
    Conditions
    Septic Shock; Refractory Shock; Norepinephrine Adverse Reaction
    Interventions
    Terlipressin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-04-03
    Completion
    2025-07-31
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock; Refractory Shock; Norepinephrine Adverse Reaction
    InterventionTerlipressin; Placebo
    PhasePhase 2
    Registry statusUnknown

  • Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate

    NCT04110418 · start 2019-02-19

    Registered record
    Registry ID
    NCT04110418
    Conditions
    Neonatal Sepsis; Refractory Shock
    Interventions
    Methylene Blue
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-02-19
    Completion
    2020-02-19
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeonatal Sepsis; Refractory Shock
    InterventionMethylene Blue
    PhasePhase 2
    Registry statusUnknown

  • Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites

    NCT03107091 · start 2017-07-15

    Registered record
    Registry ID
    NCT03107091
    Conditions
    Cirrhosis; Ascites Hepatic
    Interventions
    Terlipressin acetate continuous infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-07-15
    Completion
    2019-04-25
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis; Ascites Hepatic
    InterventionTerlipressin acetate continuous infusion
    PhasePhase 2
    Registry statusCompleted

  • An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension

    NCT01640964 · start 2013-04

    Registered record
    Registry ID
    NCT01640964
    Conditions
    Compensated Cirrhosis and Portal Hypertension
    Interventions
    Terlipressin acetate; Serelaxin (RLX030)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-04
    Completion
    2014-12
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCompensated Cirrhosis and Portal Hypertension
    InterventionTerlipressin acetate; Serelaxin (RLX030)
    PhasePhase 2
    Registry statusCompleted

  • A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

    NCT01143246 · start 2010-10-11

    Registered record
    Registry ID
    NCT01143246
    Conditions
    Hepatorenal Syndrome
    Interventions
    Terlipressin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-10-11
    Completion
    2013-05-10
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatorenal Syndrome
    InterventionTerlipressin; Placebo
    PhasePhase 3
    Registry statusCompleted